Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
| ▸ | HTR3A | P46098 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1425396 | 0.80 | — | — | |
| SCHEMBL20748212 | 0.80 | — | — | |
| SCHEMBL2113163 | 0.80 | — | — | |
| SCHEMBL13250365 | 0.76 | CCR5 (0.47) | CCR5CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL8007981 | 0.76 | CCR5 (0.47) | CCR5CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL1243243 | 0.76 | CCR5 (0.47) | CCR5CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL21722417 | 0.75 | CCR5 (0.30) | CCR5CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL27664761 | 0.75 | ALDH1A1 (0.34) | — | |
| SCHEMBL1545962 | 0.74 | CCR5 (0.53) | CCR5CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL23183144 | 0.73 | HTR2C (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7381738-B2 | Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-06-03 | — | — | US | disclosed |
| US-7288563-B2 | Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-10-30 | — | — | US | disclosed |
| US-7230022-B2 | Substituted fused bicyclic amines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-06-12 | — | — | US | disclosed |
| US-20050227960-A1 | Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2005-10-13 | — | — | US | disclosed |
| US-20050197373-A1 | Substituted fused bicyclic amines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2005-09-08 | — | — | US | disclosed |
| US-20050192276-A1 | Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2005-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050192276-A1 | Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity | CCR1, CCR2, BDKRB1 | CCR5 8/4885CHRNB2 671/4885CHRNB4 771/4885 |
| US-20050227960-A1 | Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity | CCR1, CCR2, CCR10 | CCR5 9/4885CHRNB2 509/4885CHRNB4 651/4885 |
| US-20050197373-A1 | Substituted fused bicyclic amines as modulators of chemokine receptor activity | CCR3, CCR1, CCR2 | CCR5 7/4885CHRNB2 745/4885CHRNB4 592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.